Skip to main content
SpringerLink
Log in

The Use of Antiviral Drugs in the Prevention and Treatment of Kaposi Sarcoma, Multicentric Castleman Disease and Primary Effusion Lymphoma

  • Chapter
Kaposi Sarcoma Herpesvirus: New Perspectives

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 312))

Abstract

Kaposi sarcoma-associated herpesvirus [KSHV, also known as human herpesvirus 8 (HHV-8)] is the most recently identified member of the human herpesvirus family. Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease are all associated with KSHV infection. Although the incidence of KS has declined dramatically in areas with access to highly active antiretroviral therapy, it remains the most common AIDS-associated malignancy in the developed world and is one of the most common cancers in developing nations. Current treatment options for KSHV-associated disease are ineffective, unavailable, or toxic to many affected persons. A growing body of basic science, preclinical, and observational data suggests that antiviral medications may play an important role in the prevention and treatment of KSHV-associated disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP (2002) Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin InfectDis 35:880–882

    Article  Google Scholar 

  • Bani-Sadr F, Fournier S, Molina JM (2003) Relapse of Kaposi’s sarcomain HIV-infected patients switching from a protease inhibitor toanon-nucleoside reverse transcrip-tase inhibitor-based highly active antiretroviral therapy regimen. AIDS 17:1580–1581

    Article  PubMed  Google Scholar 

  • Berezne A, Agbalika F, Oksenhendler E, Casper C, Nichols WG, Huang M-L, Corey L, Wald A (2004) Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 103:4368–4369

    Article  PubMed  CAS  Google Scholar 

  • Boivin G, Cote S, Cloutier N, Abed Y, Maguigad M, Routy JP (2002) Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi’s sarcoma and multicentric Castleman’s disease. J Med Virol 68:399–403

    Article  PubMed  CAS  Google Scholar 

  • Bottieau E, Colebunders R, Schroyens W, Van Droogenbroeck J, De Droogh E, Depraetere K, De Raeve H, Van Marck E (2000) Multicentric Castleman’s disease in 2 patients with HIV infection, unresponsive to antiviral therapy. Acta Clin Belg 55:97–101

    PubMed  CAS  Google Scholar 

  • Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B (1999) Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. Aids 13:2105–2111

    Article  PubMed  CAS  Google Scholar 

  • Broccolo F, Bossolasco S, Careddu AM, Tambussi G, Lazzarin A, Cinque P (2002) Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance. Clin Diagn Lab Immunol 9:1222–1228

    Article  PubMed  CAS  Google Scholar 

  • Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, Gudza I, Fitzpatrick L, Schooley RT (2000)Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi’s sarcoma clinical stage. AIDS 14:2109–2116

    Article  PubMed  CAS  Google Scholar 

  • Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF (1999) Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 73:4786–4793

    PubMed  CAS  Google Scholar 

  • Cannon MJ, Dollard SC, Black JB, Edlin BR, Hannah C, Hogan SE, Patel MM, Jaffe HW, Offermann MK, Spira TJ, Pellett PE, Gunthel CJ (2003) Risk factors for Kaposi’s sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 17:215–222

    Article  PubMed  CAS  Google Scholar 

  • Carroll PA, Brazeau E, Lagunoff M (2004) Kaposi’s sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 328:7–18

    Article  PubMed  CAS  Google Scholar 

  • Casper C, Nichols WG, Huang ML, Corey L, Wald A (2004) Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103:1632–1634

    Article  PubMed  CAS  Google Scholar 

  • Cattelan A, Calabro M, Gasperini P, Aversa S, Zanchetta M, Meneghetti F, De Rossi AA, Chieco-Bianchi L (2001) Acquired immunodeficiency syndrome-related Kaposi’s sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 28:44–49

    PubMed  Google Scholar 

  • Center for Disease Control (1981) Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 30:305–308

    Google Scholar 

  • Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266:1865–1869

    Article  PubMed  CAS  Google Scholar 

  • Clifford GM, Polesel J, Rickenbach M, on behalf of the Swiss HIV Cohort Study, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S (2005) Cancer Risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy 10.1093/jnci/dji072. J Natl Cancer Inst 97:425–432

    PubMed  Google Scholar 

  • Conant MA, Opp KM, Poretz D, Mills RG (1997) Reduction of Kaposi’s sarcoma lesions following treatment of AIDS with ritonovir. AIDS 11:1300–1301

    PubMed  CAS  Google Scholar 

  • Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473–3475

    Article  PubMed  CAS  Google Scholar 

  • Dittmer D, Stoddart C, Renne R, Linquist-Stepps V, Moreno ME, Bare C, McCune JM, Ganem D (1999) Experimental transmission of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J Exp Med 190:1857–1868

    Article  PubMed  CAS  Google Scholar 

  • Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, Vazquez Garcia E, Martinez Vazquez C (1998) Regression of AIDS-related Kaposi’s sarcoma following ritonavir therapy. Oral Oncol 34:236–238

    Article  PubMed  CAS  Google Scholar 

  • Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande JP, Weiss RA, Alitalo K, Boshoff C (1999) Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 96:4546–4551

    Article  PubMed  CAS  Google Scholar 

  • Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ (2002) Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94:1204–1210

    PubMed  Google Scholar 

  • Friedrichs C, Neyts J, Gaspar G, Clercq ED, Wutzler P (2004) Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res 62:121–123

    Article  PubMed  CAS  Google Scholar 

  • Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, Calvez V, Gotch F, Boshoff C, Gazzard B (2002) Prospective study of the effects of antiretroviral therapy on kaposi sarcoma-associated herpesvirus infection in patients with and without kaposi sarcoma. J Acquir Immune Defic Syndr 31:384–390

    PubMed  CAS  Google Scholar 

  • Glesby MJ, Hoover DR, Weng S, Graham NM, Phair JP, Detels R, Ho M, Saah AJ (1996) Use of antiherpes drugs and the risk of Kaposi’s sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 173:1477–1480

    PubMed  CAS  Google Scholar 

  • Grandadam M, Dupin N, Calvez V, Gorin I, Blum L, Kernbaum S, Sicard D, Buisson Y, Agut H, Escande JP, Huraux JM (1997) Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman’s disease are associated with a high increase in Kaposi’s sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 175:1198–1201

    Article  PubMed  CAS  Google Scholar 

  • Gustafson EA, Schinazi RF, Fingeroth JD (2000) Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol 74:684–692

    Article  PubMed  CAS  Google Scholar 

  • Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM (2001) Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 15:280–282

    Article  PubMed  CAS  Google Scholar 

  • Huang LM, Chao MF, Chen MY, Shih H, Chiang YP, Chuang CY, Lee CY (2001) Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem 276:13427–13432

    Article  PubMed  CAS  Google Scholar 

  • Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H, William DC, Laubenstein LJ (1981) Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet 2:598–600

    Article  PubMed  CAS  Google Scholar 

  • Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, Griffiths PD, Contopoulos-Ioannidis DG, Lau J, Pavia AT, Saag MS, Spruance SL, Youle MS (1998) Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 178:349–359

    PubMed  CAS  Google Scholar 

  • Joffe MM, Hoover DR, Jacobson LP, Kingsley L, Chmiel JS, Visscher BR (1997) Effect of treatment with zidovudine on subsequent incidence of Kaposi’s sarcoma. Clin Infect Dis 25:1125–1133

    PubMed  CAS  Google Scholar 

  • Jung C, Bogner JR, Goebel F (1998) Resolution of severe Kaposi’s sarcoma after initiation of antiretroviral triple therapy. Eur J Med Res 3:439–442

    PubMed  CAS  Google Scholar 

  • Katano H, Sato Y, Itoh H, Sata T (2001) Expression of human herpesvirus 8 (HHV-8)-encoded immediate early protein, open reading frame 50, in HHV-8-associated diseases. J Hum Virol 4:96–102

    PubMed  CAS  Google Scholar 

  • Katano H, Sato Y, Kurata T, Mori S, Sata T (2000) Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi’s sarcoma, and multicentric Castleman’s disease. Virology 269:335–344

    Article  PubMed  CAS  Google Scholar 

  • Kedes DH, Ganem D (1997) Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 99:2082–2086

    Article  PubMed  CAS  Google Scholar 

  • Klass CM, Krug LT, Pozharskaya VP, Offermann MK (2005) The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood: 2004-2009-3569

    Google Scholar 

  • Krischer J, Rutschmann O, Hirschel B, Vollenweider-Roten S, Saurat JH, Pechere M (1998) Regression of Kaposi’s sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad Dermatol 38:594–598

    Article  PubMed  CAS  Google Scholar 

  • Krown SE (2004) Highly active antiretroviral therapy in AIDS-associated Kaposi’s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi’s sarcoma. J Clin Oncol 22:399–402

    Article  PubMed  Google Scholar 

  • Krug LT, Pozharskaya VP, Yu Y, Inoue N, Offermann MK (2004) Inhibition of infection and replication of human herpesvirus 8 in microvascular endothelial cells by α interferon and phosphonoformic acid. J Virol 78:8359–8371

    Article  PubMed  CAS  Google Scholar 

  • Leao JC, Kumar N, McLean KA, Porter SR, Scully CM, Swan AV, Teo CG (2000) Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients. J Med Virol 62:416–420

    Article  PubMed  CAS  Google Scholar 

  • Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, Danne O, Calvo F (1998) Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS 12: F45–F49

    Article  PubMed  CAS  Google Scholar 

  • Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, Pluda JM, Marshall V, Walters M, Welles L, Rodriguez-Chavez IR, Pittaluga S, Tosato G, Yarchoan R (2003) A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis 187:149–153

    Article  PubMed  CAS  Google Scholar 

  • Lock MJ, Thorley N, Teo J, Emery VC (2002) Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J Antimicrob Chemother 49:359–366

    Article  PubMed  CAS  Google Scholar 

  • Lorenzen T, Albrecht D, Paech V, Meyer T, Hoffmann C, Stoehr A, Degen O, Stellbrink HJ, Meigel WN, Arndt R, Plettenberg A (2002) HHV-8 DNA in blood and the development of HIV-associated Kaposi’s sarcoma in the era of HAART—a prospective evaluation. Eur J Med Res 7:283–286

    PubMed  CAS  Google Scholar 

  • Lu M, Suen J, Frias C, Pfeiffer R, Tsai M-H, Chuang E, Zeichner SL (2004) Dissection of the Kaposi’s sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J Virol 78:13637–13652

    Article  PubMed  CAS  Google Scholar 

  • Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A, Ravazzini L, Potenza L, Riva G, Morselli M, Longo G, Cavanna L, Roncaglia R, Torelli G (2005) Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 19:473–476

    Article  PubMed  CAS  Google Scholar 

  • Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340:1063–1070

    Article  PubMed  CAS  Google Scholar 

  • Martinelli C, Zazzi M, Ambu S, Bartolozzi D, Corsi P, Leoncini F (1998) Complete regression of AIDS-related Kaposi’s sarcoma-associated human herpesvirus-8 during therapy with indinavir. AIDS 12:1717–1719

    PubMed  CAS  Google Scholar 

  • McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632–1639

    Article  PubMed  CAS  Google Scholar 

  • Medveczky MM, Horvath E, Lund T, Medveczky PG (1997) In vitro antiviral drug sensitivity of the Kaposi’s sarcoma-associated herpesvirus. AIDS 11:1327–1332

    Article  PubMed  CAS  Google Scholar 

  • Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN (1996) Antiherpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 10:1101–1105

    Article  PubMed  CAS  Google Scholar 

  • Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL (1997) Regression of AIDS-related Kaposi’s sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 11:261–262

    PubMed  CAS  Google Scholar 

  • Neyts J, De Clercq E (1997) Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 41:2754–2756

    PubMed  CAS  Google Scholar 

  • Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F (2000) High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 96:2069–2073

    PubMed  CAS  Google Scholar 

  • Pastore RD, Chadburn A, Kripas C, Schattner EJ (2000) Novel association of haemophagocytic syndrome with Kaposi’s sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol 111:1112–1115

    Article  PubMed  CAS  Google Scholar 

  • Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MS, Jr., Weichold FF (2002) Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99:3771–3779

    Article  PubMed  CAS  Google Scholar 

  • Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, Agbalika F, Lascoux C, Ponscarme D, Morel P, Calvo F, Lebbe C (2001) Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi’s sarcoma to highly active antiretroviral therapy. J Invest Dermatol 117:858–863

    Article  PubMed  CAS  Google Scholar 

  • Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Gazzard B (2003) A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS 17: F17–F22

    Article  PubMed  CAS  Google Scholar 

  • Renne R, Lagunoff M, Zhong W, Ganem D (1996) The size and conformation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol 70:8151–8154

    PubMed  CAS  Google Scholar 

  • Rey D, Schmitt MP, Partisani M, Hess-Kempf G, Krantz V, de Mautort E, Bernard-Henry C, Priester M, Cheneau C, Lang JM (2001) Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr 27:459–462

    PubMed  CAS  Google Scholar 

  • Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P (1978) 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272:583–585

    Article  PubMed  CAS  Google Scholar 

  • Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B (2002) HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8:225–232

    Article  PubMed  CAS  Google Scholar 

  • Sgadari C, Monini P, Barillari G, Ensoli B (2003) Use of HIV protease inhibitors to block Kaposi’s sarcoma and tumour growth. Lancet Oncol 4:537–547

    Article  PubMed  CAS  Google Scholar 

  • Shimba N, Nomura AM, Marnett AB, Craik CS (2004) Herpesvirus protease inhibition by dimer disruption. J Virol 78:6657–6665

    Article  PubMed  CAS  Google Scholar 

  • Sirianni MC, Vincenzi L, Topino S, Giovannetti A, Mazzetta F, Libi F, Scaramuzzi D, Andreoni M, Pinter E, Baccarini S, Rezza G, Monini P, Ensoli B (2002) NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi’s sarcoma. Eur J Immunol 32:2711–2720

    Article  PubMed  CAS  Google Scholar 

  • Stebbing J, Portsmouth S, Nelson M, Mandalia S, Kandil H, Alexander N, Davies L, Brock C, Bower M, Gazzard B (2004) The efficacy of ritonavir in the prevention of AIDS-related Kaposi’s sarcoma. Int J Cancer 108:631–633

    Article  PubMed  CAS  Google Scholar 

  • Tavio M, Nasti G, Spina M, Errante D, Vaccher E, Tirelli U (1998) Highly active antiretroviral therapy in HIV-related Kaposi’s sarcoma. Ann Oncol 9:923

    Article  PubMed  CAS  Google Scholar 

  • Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FE, Aldam DM, Denton AS, et al. (1995) Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma Lancet 346:799–802

    Article  PubMed  CAS  Google Scholar 

  • Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N, Kubo T, Marcelin A, Calvez V, Weiss R, Gazzard B, Boshoff C, Gotch F (2002) Identification of Kaposi’s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 76:2634–2640

    Article  PubMed  CAS  Google Scholar 

  • Zietz C, Bogner JR, Goebel FD, Lohrs U (1999) An unusual cluster of cases of Castle-man’s disease during highly active antiretroviral therapy for AIDS. N Engl J Med 340:1923–1924

    Article  PubMed  CAS  Google Scholar 

  • Zoeteweij JP, Eyes ST, Orenstein JM, Kawamura T, Wu L, Chandran B, Forghani B, Blauvelt A (1999) Identification and rapid quantification of early-and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents. J Virol 73:5894–5902

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Washington Virology Research Clinic, 600 Broadway, Suite 400, Seattle, WA, 98122, USA

    C. Casper & A. Wald

Authors
  1. C. Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Wald
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK

    Chris Boshoff MRCP, Ph.D.

  2. Wohl Virion Centre, Division of Infection and Immunity, University College London, 46 Cleveland Street, London, W1T 4JF, UK

    Robin A. Weiss Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Casper, C., Wald, A. (2007). The Use of Antiviral Drugs in the Prevention and Treatment of Kaposi Sarcoma, Multicentric Castleman Disease and Primary Effusion Lymphoma. In: Boshoff, C., Weiss, R.A. (eds) Kaposi Sarcoma Herpesvirus: New Perspectives. Current Topics in Microbiology and Immunology, vol 312. Springer, Berlin, Heidelberg . https://doi.org/10.1007/978-3-540-34344-8_11

Download citation

Publish with us

Policies and ethics

Search

Navigation